Keensight Capital hopes to mobilize significant resources to help the management team to implement a strategic development plan to become a European leader.

“We are very pleased to team up with Keensight Capital and welcome such a respected investor as a partner. Thanks to their support, we intend to develop our offer and know-how on existing technologies (microbial, mammalian and viral vector platforms), in the context of a strongly growing biopharma CDmO market with significant capacity shortages. We are convinced that with their deep knowledge of the healthcare sector, and their extensive international network, we will together enable our company to fulfil its ambitions to become the market’s first choice full service CDmO,” said Knut Ringbom, Chief Executive Officer of Biovian.

Biovian has all assets to fit our investment strategy

With this operation, Keensight Capital and the ERES funds invest a majority stake in order to support Biovian to increase capacities, both in the complex microbial development space and in the booming viral vector and gene therapy market, expand and further internationalize its current client base and further extend the one-stop-shop concept and reinforce its services portfolio to support its clients over additional stages of their products’ life cycle.

“We are extremely enthusiastic to have gained the trust of Dr. Knut Ringbom and his highly experienced management team. We identified the company for its strong international footprint as well as its solid positioning within the strongest growth segment of the pharma industry. As a reference player in this complex market segment characterized by a stringent regulatory environment, combined with a profitable growth, Biovian has all assets to fit our investment strategy. We will accompany Biovian’s management to create tomorrow’s European leader in the Biologics CDmO space,” said Magdalena Svensson, Partner at Keensight Capital.